Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma


Neuroblastoma, a tumour derived from the peripheral sympathetic nervous system, is one of the most frequent solid tumours in childhood1,2. It usually occurs sporadically but familial cases are observed, with a subset of cases occurring in association with congenital malformations of the neural crest being linked to germline mutations of the PHOX2B gene1,2,3,4. Here we conducted genome-wide comparative genomic hybridization analysis on a large series of neuroblastomas. Copy number increase at the locus encoding the anaplastic lymphoma kinase (ALK)5 tyrosine kinase receptor was observed recurrently. One particularly informative case presented a high-level gene amplification that was strictly limited to ALK, indicating that this gene may contribute on its own to neuroblastoma development. Through subsequent direct sequencing of cell lines and primary tumour DNAs we identified somatic mutations of the ALK kinase domain that mainly clustered in two hotspots. Germline mutations were observed in two neuroblastoma families, indicating that ALK is a neuroblastoma predisposition gene. Mutated ALK proteins were overexpressed, hyperphosphorylated and showed constitutive kinase activity. The knockdown of ALK expression in ALK-mutated cells, but also in cell lines overexpressing a wild-type ALK, led to a marked decrease of cell proliferation. Altogether, these data identify ALK as a critical player in neuroblastoma development that may hence represent a very attractive therapeutic target in this disease that is still frequently fatal with current treatments6,7.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type



Prices may be subject to local taxes which are calculated during checkout

Figure 1: Genetic characteristics of ALK in neuroblastoma.
Figure 2: Functional characterization of mutated ALK.

Accession codes

Primary accessions

Gene Expression Omnibus

Data deposits

Microarray data have been submitted to the Gene Expression Omnibus ( public database. The accession numbers for gene expression profiles of neuroblastoma samples and SNP data for case NB-99 displayed in Fig. 1c are GSE12460 and GSE12461, respectively.


  1. Maris, J. M., Hogarty, M. D., Bagatell, R. & Cohn, S. L. Neuroblastoma. Lancet 369, 2106–2120 (2007)

    Article  CAS  Google Scholar 

  2. Brodeur, G. M. Neuroblastoma: biological insights into a clinical enigma. Nature Rev. Cancer 3, 203–216 (2003)

    Article  CAS  Google Scholar 

  3. Tonini, G. P., Longo, L., Coco, S. & Perri, P. Familial neuroblastoma: a complex heritable disease. Cancer Lett. 197, 41–45 (2003)

    Article  CAS  Google Scholar 

  4. Trochet, D. et al. Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma. Am. J. Hum. Genet. 74, 761–764 (2004)

    Article  CAS  Google Scholar 

  5. Chiarle, R., Voena, C., Ambrogio, C., Piva, R. & Inghirami, G. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nature Rev. Cancer 8, 11–23 (2008)

    Article  CAS  Google Scholar 

  6. Galkin, A. V. et al. Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proc. Natl Acad. Sci. USA 104, 270–275 (2007)

    Article  ADS  CAS  Google Scholar 

  7. Li, R. & Morris, S. W. Development of anaplastic lymphoma (ALK) small-molecule inhibitors for cancer therapy. Med. Res. Rev. 28, 372–412 (2008)

    Article  CAS  Google Scholar 

  8. Fix, A. et al. Characterization of amplicons in neuroblastoma. High-resolution mapping using DNA microarrays, relationship with outcome, and identification of overexpressed genes. Genes Chromosom. Cancer 47, 819–834 (2008)

    Article  CAS  Google Scholar 

  9. Schwab, M. et al. Chromosome localization in normal human cells and neuroblastomas of a gene related to c-myc. Nature 308, 288–291 (1984)

    Article  ADS  CAS  Google Scholar 

  10. Lamant, L. et al. Expression of the ALK tyrosine kinase gene in neuroblastoma. Am. J. Pathol. 156, 1711–1721 (2000)

    Article  CAS  Google Scholar 

  11. Osajima-Hakomori, Y. et al. Biological role of anaplastic lymphoma kinase in neuroblastoma. Am. J. Pathol. 167, 213–222 (2005)

    Article  CAS  Google Scholar 

  12. Miyake, I. et al. Activation of anaplastic lymphoma kinase is responsible for hyperphosphorylation of ShcC in neuroblastoma cell lines. Oncogene 21, 5823–5834 (2002)

    Article  CAS  Google Scholar 

  13. Blume-Jensen, P. & Hunter, T. Oncogenic kinase signalling. Nature 411, 355–365 (2001)

    Article  ADS  CAS  Google Scholar 

  14. Rikova, K. et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131, 1190–1203 (2007)

    Article  CAS  Google Scholar 

  15. Zou, H. Y. et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 67, 4408–4417 (2007)

    Article  CAS  Google Scholar 

  16. McDermott, U. et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res. 68, 3389–3395 (2008)

    Article  CAS  Google Scholar 

  17. Morris, S. W. et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science 263, 1281–1284 (1994)

    Article  ADS  CAS  Google Scholar 

  18. Griffin, C. A. et al. Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors. Cancer Res. 59, 2276–2280 (1999)

    Google Scholar 

  19. Soda, M. et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448, 561–566 (2007)

    Article  ADS  CAS  Google Scholar 

  20. Chiarle, R. et al. NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. Blood 101, 1919–1927 (2003)

    Article  CAS  Google Scholar 

  21. Fujimoto, J. et al. Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5). Proc. Natl Acad. Sci. USA 93, 4181–4186 (1996)

    Article  ADS  CAS  Google Scholar 

  22. Hubbard, S. R. Juxtamembrane autoinhibition in receptor tyrosine kinase. Nature Rev. Mol. Cell Biol. 5, 464–471 (2004)

    Article  CAS  Google Scholar 

  23. Renneville, A. et al. Cooperating gene mutations in acute myeloid leukaemia: a review of the literature. Leukemia 22, 915–931 (2008)

    Article  CAS  Google Scholar 

  24. Gilliland, G. & Griffin, G. The roles of FLT3 in hematopoiesis and leukaemia. Blood 100, 1532–1542 (2002)

    Article  CAS  Google Scholar 

  25. Fröhling, S. et al. Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Cancer Cell 12, 501–513 (2007)

    Article  Google Scholar 

  26. Chiarle, R. et al. The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination. Nature. Med. 14, 676–680 (2008)

    Article  CAS  Google Scholar 

  27. Vincent-Salomon, A., Raynal, V., Lucchesi, C., Gruel, N. & Delattre, O. ESR1 gene amplification in breast cancer: a common phenomenon? Nature Genet. 40, 809 (2008)

    Article  CAS  Google Scholar 

Download references


We are grateful to F. Moreau-Gachelin, I. Gallais, D. Surdez, F. Tirode, A. Fix, F. Bourdeaut, A. Almeida, C. Lucchesi, S. Roman Roman, B. Bressac, J. Bénard and G. Vassal for their critical help. We thank C. Decraene, D. Gentien and B. Albaud from the translational department of Institut Curie for profiling the paediatric tumours, and P. Rosa and E. Barillot for the development of bioinformatic tools. We thank M. Lathrop and the Centre National de Génotypage for the Affymetrix 100K SNP analysis and A. Chompret for collecting families. This work was supported by grants from the Agence Nationale pour la Recherche, the Institut National du Cancer, the Ligue Nationale contre le Cancer (Equipe labellisée and CIT project), the APAESIC (Association des Parents et des Amis des Enfants Soignés à l’Institut Curie), the Association Hubert Gouin, les amis de Claire, Les Bagouz à Manon and Enfance et Santé. A.P. and V.C. are supported by the Comité de l'Ain of the Ligue Nationale contre le Cancer.

Author Contributions I.J.-L., D.L., A.R., L.P., V.C. and V.R. generated the data; I.J.-L., G.P., A.P., J.M., J.A., S.L. and O.D. made the study design and follow-up; L.B., V.C., A.P., G.S., D.V.-C., T.F., S.L. and J.A. contributed biological materials that were used in this study.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Olivier Delattre.

Supplementary information

Supplementary Information

This file contains Supplementary Figures 1 and 2 with Legends. (PDF 111 kb)

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Janoueix-Lerosey, I., Lequin, D., Brugières, L. et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 455, 967–970 (2008).

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI:

This article is cited by


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing